Introduction {#sec1_1}
============

Chronic hepatitis C virus (HCV) infection is a major worldwide cause of liver-related deaths, including those caused by cirrhosis and hepatocellular carcinoma. The eradication of HCV using interferon-based treatment improves liver-related mortality and reduces the risk of hepatocellular carcinoma development. Recently, interferon-free direct-acting antiviral therapy was used, which showed an excellent rate of HCV eradication among patients with chronic HCV genotype 1b, including those with prior interferon-based treatment failure \[[@B1]\]. However, interferon-based therapy is still a treatment option \[[@B2]\], and negativity for HCV RNA at the end of antiviral treatment (end-of-treatment response; ETR) is essential to achieve the viral clearance of chronic infection \[[@B3]\]. Although delayed viral clearance after the completion of 24--48 weeks of interferon-based therapy is rarely reported, such a situation has not been observed among patients with the early discontinuation of therapy. Here, we report a case of HCV clearance at 7 months after a 6-week treatment with peginterferon (pegIFN) plus ribavirin (RBV).

Case Report {#sec1_2}
===========

A 76-year-old Japanese male (height, 161 cm; weight, 63 kg) with chronic HCV genotype 1b infection had initiated treatment with pegIFN α-2b plus RBV. Previously, he had been followed up for inactive chronic hepatitis for 15 years, with alanine aminotransferase (ALT) levels \<40 IU/l, which had fluctuated from 40 to 140 IU/l for a year before the initiation of the latest treatment regimen. His medical history included hypertension, hyperuricemia, and resistant gastroesophageal reflux disease, which were being treated with nifedipine, candesartan cilexetil, allopurinol, and lansoprazole for more than 5 years. Pretreatment liver biopsy showed grade 1 inflammation and stage 1/4 fibrosis. Laboratory examinations (table [1](#T1){ref-type="table"}) revealed the following biochemical levels: ALT, 129 IU/l; albumin, 4.3 g/dl; γ-glutamyl transpeptidase, 72 IU/l; platelet count, 23.6 × 10^4^/µl, and α-fetoprotein, 4.9 ng/ml. Hepatitis C viral load was 5.3 log IU/ml. Antibody to human immunodeficiency virus and antinuclear antibodies were negative. Genetic studies revealed TT of IL28B (rs8099917) and human leukocyte antigen (HLA)-DRB1\*01: 01/08: 03. After the initiation of therapy, he reported a loss of appetite at week 2 and complained of anxiety, irritability, insomnia, and poor concentration at week 3. Although daily etizolam before sleep was started, he experienced poor appetite, taste disorder, and weight loss of 2 kg from the initiation of therapy. Therefore, sulpiride was added, and the RBV dose was reduced from 800 to 600 mg per day because of anemia. However, symptoms did not subside with a further weight loss of 1 kg and the progression of anemia; thus, the RBV dose was reduced to 400 mg/day. Nonetheless, the symptoms persisted, and he reported depression at week 6, which prompted treatment discontinuation. Following this, the symptoms slowly but gradually subsided, and he recovered after 5 weeks. Meanwhile, the HCV RNA load decreased to weakly positive, with measured values of less than 1.2 log IU/ml at week 4, which persisted at this level until 12 days after the discontinuation of treatment (fig. [1](#F1){ref-type="fig"}). Then, the load gradually increased to 2.6 log IU/ml and 4.3 log IU/ml at 7--10 and 19 weeks after discontinuation, respectively. Concurrently, serum ALT levels, which had persisted at levels of less than 34 IU/l after the discontinuation of treatment, increased to 44 IU/l. A posttreatment ultrasound exam revealed a 1.0-cm bladder tumor, which was diagnosed by urinary cytology as class V, and the patient was treated by transurethral resection of the bladder tumor (TUR-BT) at week 26 of discontinuation. Histological examination revealed low-grade, noninvasive papillary urothelial carcinoma. Serum ALT had normalized (16 IU/l) at 1 week before TUR-BT, and HCV RNA was found to be negative at 11 days after surgery (28 weeks after the discontinuation of antiviral therapy), which has been maintained along with low levels (\<25 IU/l) of ALT for more than 4 years.

Discussion {#sec1_3}
==========

This patient showed an unusual and unique clinical course of delayed viral clearance despite only 6 weeks of pegIFN plus RBV therapy, without the achievement of HCV RNA negativity. There are relatively few reports of delayed viral clearance among patients with non-ETR and those with relapse after pegIFN plus RBV therapy; all these patients had completed 24--48 weeks of therapy, and almost all had genotype 2 or 3 and were aged \<60 years \[[@B4], [@B5], [@B6]\]. Compared with those cases, our patient was unique in terms of being infected with HCV genotype 1b, older, and treated for only 6 weeks without achieving ETR. Although the mechanism underlying delayed viral clearance remains unknown, we speculate two possibilities for this patient. One is an immunological modification due to surgical stress caused by TUR-BT, and the other is a delayed effect of pegIFN plus RBV therapy. It has been reported that surgical stress or invasive treatment can sometimes induce the clearance of HCV RNA \[[@B7], [@B8]\], but this is not applicable to this case because it is quite unlikely that HCV RNA with 4.3 log copies/ml was eliminated within 11 days after TUR-BT. Furthermore, although HCV RNA was not examined, the normalization of serum ALT had already occurred before TUR-BT. Therefore, we alternatively consider the immunological effect induced by pegIFN plus RBV therapy. Chronic infection with HCV is characterized by HCV-specific T cell dysfunction, and T cell function is considered to play an essential role in the elimination of the virus \[[@B9]\]. Although it is controversial whether pegIFN plus RBV therapy restores T cell function, the marked restoration of HCV-specific CD8 T cells was observed from 1 month after treatment in patients with a sustained viral response \[[@B10]\], and a correlation between the restoration of HCV-specific CD8+ T-cell function and early/sustained viral response \[[@B11]\] has been reported. In this case, HCV RNA rapidly decreased after treatment, although the levels remained positive at \<1.2 log IU/ml at week 4, and the low levels of viral load persisted for at least 10 weeks after the discontinuation of therapy, suggesting immunological recovery from HCV infection. Furthermore, the mild elevation of ALT at 19 weeks could be considered as the T cell response against increased HCV RNA. This phenomenon is well known in patients with chronic hepatitis B virus (HBV) infection, in whom ALT flare occurs with a preceding increase in HBV DNA, often resulting in continuous virus suppression. The immunological response observed in this phenomenon is also well understood \[[@B12]\]. In our patient, although the elevation of ALT was mild, a similar mechanism was presumed.

This patient had a genetic background of HLA-B1\*01: 01 and TT of IL28B rs8099917. The cellular immune responses coordinated by CD4 and CD8 T cells are genetically predetermined by the hosts' HLA molecules. In addition, the IL28B gene encodes an innate interferon. Recently, several studies have revealed that the class II DRB1\*01: 01 HLA allele and the C and T alleles of IL28B (rs12979860 and rs8099917, respectively) are associated with the spontaneous clearance of HCV \[[@B13], [@B14], [@B15]\]. Furthermore, HLA-DRB1\*01 is suspected to be associated with delayed viral clearance after pegIFN plus RBV therapy \[[@B4]\]. Therefore, the genetic background of this patient may be related to the viral clearance after treatment discontinuation.

In conclusion, interferon-based therapy remains a viable treatment option for chronic HCV infection, and virological follow-up is necessary even for patients with non-ETR, particularly for those with persistent low viral loads after treatment.
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Laboratory data before treatment with pegIFN plus RBV

  ------- --------------- --------- ------------ ------------------ -------------------
  WBC     7,300/µl        ALP       347 IU/l     HCV genotype       1b
  Hb      16.0 g/dl       γ-GTP     38 IU/l      RNA load           5.3 log IU/ml
  Hct     47.1%           TP        8.3 g/dl     ISDR               mixed type (6, 1)
  Plt     24.5×10^4^/µl   ALB       4.3 g/dl     Core 70AA          competitive type
  PT      114.0%          TC        203 mg/dl    Core 91AA          wild type
  T.Bil   0.6 mg/dl       UA        5.7 mg/dl                       
  D.Bil   0.1 mg/dl       UN        13.8 mg/dl   IL-28B rs8099917   T/T
  AST     36 IU/l         Cre       0.98 mg/dl   HLA DR             B1\*01:01/08:03
  ALT     43 IU/l         Glucose   95 mg/dl                        
  LDH     193 IU/l        AFP       4.9 ng/ml                       
  ------- --------------- --------- ------------ ------------------ -------------------

WBC = White blood cell count; Hb = hemoglobin; Hct = hematocrit; Plt = platelet; PT = prothrombin time; T.Bil = total bilirubin; D.Bil = direct bilirubin; AST = aspartate aminotransferase; LDH = lactate dehydrogenase; ALP = alkaline phosphatase; γ-GTP = γ-glutamyl transferase; TP = total protein; Alb = albumin; TC = total cholesterol; UA = uric acid; UN = urea nitrogen; Cre = creatinine; AFP = α-fetoprotein; ISDR = interferon sensitivity-determining region; Core 70AA = core 70 amino acid; IL-28B = interleukin-28B; HLA = human leukocyte antigen.
